VolitionRX Limited (NYSEAMERICAN:VNRX) Receives $2.33 Consensus PT from Analysts

VolitionRX Limited (NYSEAMERICAN:VNRX) has received a consensus rating of “Moderate Buy” from the five ratings firms that are presently covering the firm, MarketBeat.com reports. Three investment analysts have rated the stock with a hold recommendation, one has given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $2.3333.

Several research analysts have weighed in on the company. D. Boral Capital reiterated a “hold” rating on shares of VolitionRX in a research note on Monday. Citigroup downgraded VolitionRX to a “hold” rating in a research note on Monday. Finally, HC Wainwright lowered their target price on VolitionRX from $1.50 to $1.00 and set a “buy” rating on the stock in a research note on Thursday, April 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of VolitionRX in the second quarter valued at approximately $52,000. Virtu Financial LLC purchased a new stake in shares of VolitionRX in the third quarter valued at approximately $28,000. Citadel Advisors LLC boosted its stake in shares of VolitionRX by 70.1% in the third quarter. Citadel Advisors LLC now owns 329,520 shares of the medical research company’s stock valued at $224,000 after buying an additional 135,775 shares in the last quarter. Lagoda Investment Management L.P. boosted its stake in shares of VolitionRX by 6.7% in the third quarter. Lagoda Investment Management L.P. now owns 12,487,000 shares of the medical research company’s stock valued at $8,476,000 after buying an additional 782,000 shares in the last quarter. Finally, Armistice Capital LLC boosted its stake in shares of VolitionRX by 10.4% in the third quarter. Armistice Capital LLC now owns 9,380,425 shares of the medical research company’s stock valued at $6,367,000 after buying an additional 887,351 shares in the last quarter. 8.09% of the stock is currently owned by hedge funds and other institutional investors.

VolitionRX Stock Up 0.4%

VNRX opened at $0.16 on Monday. The firm has a market cap of $24.99 million, a price-to-earnings ratio of -0.72 and a beta of 1.33. VolitionRX has a 52 week low of $0.15 and a 52 week high of $0.94. The business’s 50 day moving average is $0.19 and its two-hundred day moving average is $0.29.

Shares of VolitionRX are scheduled to reverse split before the market opens on Tuesday, April 28th. The 1-20 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Monday, April 27th.

VolitionRX (NYSEAMERICAN:VNRX) last announced its earnings results on Tuesday, March 31st. The medical research company reported ($0.05) earnings per share for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $0.45 million during the quarter, compared to analysts’ expectations of $0.71 million. Equities analysts expect that VolitionRX will post -0.11 EPS for the current fiscal year.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.